Cyclophosphamide
Anaplastic Thyroid Carcinomas
Chongqing Precision Biotech Co., LtdSmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
7 Active assets in the Anaplastic Thyroid Carcinomas cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Chongqing Precision Biotech Co., Ltd | Phase 2 | B |
Levoleucovorin Hospices Civils de Lyon | Phase 2 | CCC |
FLUOROURACILUM Hospices Civils de Lyon | Phase 2 | CCC |
Eloxatin Hospices Civils de Lyon | Phase 2 | CCC |
Zimberelimab Hospices Civils de Lyon | Phase 2 | CCC |
Domvanalimab Hospices Civils de Lyon | Phase 2 | CCC |
cd70-targeting car-t cells Chongqing Precision Biotech Co., Ltd | Phase 1 | CC |
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →